Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Pharmaceutical giant Pfizer is in the early stages of a review for antidepressant drug Zoloft, a competitor of Eli Lilly & Co.’s Prozac and SmithKline Beecham’s Paxil, sources said.
The New York-based company has hired ADvice & ADvisors in New York to manage the search, said sources. The consultant declined comment and the client could not be reached.
Billings are estimated at $50 million.
Sources indicated that the client wants to advertise Zoloft more broadly to consumers via a general-market agency.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in